In recent years, there has been a major paradigm shift in the management of non-small cell
lung cancer (NSCLC). NSCLC should now be further sub-classified by histology and driver …

Non-small-cell lung cancer is one of the leading causes of deaths from cancer worldwide.
Therefore, improvements in diagnostics and treatments are urgently needed. In this review …

Objective To establish evidence-based recommendations for the molecular analysis of lung
cancers that are that are required to guide EGFR-and ALK-directed therapies, addressing …

Lung cancer has shown a decrease in incidence and mortality in recent decades; however,
it remains one of the cancers with the highest incidence and ranks first in cancerrelated …

To complement the existing treatment guidelines for all tumour types, ESMO organises
consensus conferences to focus on specific issues in each type of tumour. The Second …

Background Anaplastic lymphoma kinase (ALK) inhibition using crizotinib has become the
standard of care in advancedALK-rearranged non-small cell lung cancer (NSCLC), but the …

In non-small cell lung cancer, epidermal growth factor receptor gene mutations and
anaplastic lymphoma kinase (ALK) gene rearrangements have a major impact upon the …

Over the past decade, the growing interest in targeted lung cancer therapy has guided
researchers toward the cutting edge of controlled drug delivery, particularly magnetic …

Abstract Crizotinib, an ALK/MET/ROS1 inhibitor, was approved by the US Food and Drug
Administration for the treatment of anaplastic lymphoma kinase (ALK)-rearranged non-small …

Until recently, the division of pulmonary carcinomas into small cell lung cancer (SCLC) and
non-small cell lung cancer (NSCLC) was adequate for therapy selection. Due to the …